Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21290462 | 0.82 | HRH4 (0.45) | HRH4HRH3ALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL13210035 | 0.74 | — | — | |
| SCHEMBL17310768 | 0.74 | — | — | |
| SCHEMBL15367992 | 0.71 | CYP1A2 (0.34) | CYP1A2CYP2C19 | |
| SCHEMBL2576444 | 0.71 | — | — | |
| SCHEMBL21870638 | 0.70 | USP2 (0.41) | HRH4HRH3IDO1ALDH1A1CYP1A2 | |
| SCHEMBL1998851 | 0.69 | — | — | |
| SCHEMBL1998849 | 0.67 | — | — | |
| SCHEMBL17252910 | 0.67 | NPSR1 (0.42) | ALDH1A1 | |
| SCHEMBL21290780 | 0.64 | HRH4 (0.41) | HRH4HRH3ALDH1A1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4026835-A2 | PD-1/PD-L1 INHIBITORS | Gilead Sciences, Inc. (US) | 2022-07-13 | — | — | EP | disclosed |
| WO-2019160882-A1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2019-08-22 | — | — | WO | disclosed |
| US-20110098471-A1 | OXAZOLIDINONE DERIVATIVE HAVING FUSED RING | RESEARCH FOUNDATION ITSUU LABORATORY (JP) | 2011-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098471-A1 | OXAZOLIDINONE DERIVATIVE HAVING FUSED RING | OXER1, ALOX12, CYP1A1 | HRH4 175/4885HRH3 318/4885IDO1 199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.